Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Effect of Left Ventricular Morphology on Right Ventricular Systolic Function in Hypoplastic Left Heart Syndrome
O’Byrne, Megan M., Reece, Chelsea L., Young, Phillip M. , Wang, Alan , Qureshi, M. Yasir , Kelle, Angela M. , O’Leary, Patrick

Mayo Clinic

Pediatrics | March 1, 2023 | Volume: 146 | Issue: 1_MeetingAbstract | Pages: 631-631

10.1542/peds.146.1ma7.631a Get It

Are In-Person Trainee Interviews a Relic of the Past?
Shafa, Michelle Linke, Wang, Chris , Christensen, Julie

Mayo Clinic

American Journal of Psychiatry Residents' Journal | March 1, 2023 | Volume: 18 | Issue: 3 | Pages: 21-22

10.1176/appi.ajp-rj.2023.180307 Get It

Multimodal mapping of regional brain vulnerability to focal cortical dysplasia
Lee, Hyo M., Hong, Seok‐Jun , Gill, Ravnoor , Caldairou, Benoît , Wang, Irène , Deleo, Francesco , Schrader, Dewi , Bartolomei, Fabrice , Barba, Carmen , Cascino, Gregory D. , Guerrini, Renzo , Bernhardt, Boris C. , Bernasconi, Neda , Bernasconi, Andrea , Zhang, Jianguo , Bartolomei, Fabrice , Sisodiya, Sanjay , Jackson, Graeme , Wong-Kisiel, Lily, Bernasconi, Andrea , Guerrini, Renzo , Guye, Maxime , Cho, Kyoo Ho , Barba, Carmen , Jackson, Graeme D. , Hogan, R Edward , Wong‐Kisiel, Lily C. , Schulze‐Bonhage, Andreas , Lopes‐Cendes, Íscia , Cendes, Fernando

Mayo Clinic

Brain | February 28, 2023 | Volume: 146 | Issue: 8 | Pages: 3404-3415

10.1093/brain/awad060 | PMID 36852571 Get It

AbstractFocal cortical dysplasia (FCD) type II is a highly epileptogenic developmental malformation and a common cause of surgically treated drug-resistant epilepsy. While clinical observations suggest frequent occurrence in the frontal lobe, mechanisms for such propensity remain unexplored. Here, we hypothesized that cortex-wide spatial associations of FCD distribution with cortical cytoarchitecture, gene expression and organizational axes may offer complementary insights into processes that predispose given cortical regions to harbour FCD.We mapped the cortex-wide MRI distribution of FCDs in 337 patients collected from 13 sites worldwide. We then determined its associations with (i) cytoarchitectural features using histological atlases by Von Economo and Koskinas and BigBrain; (ii) whole-brain gene expression and spatiotemporal dynamics from prenatal to adulthood stages using the Allen Human Brain Atlas and PsychENCODE BrainSpan; and (iii) macroscale developmental axes of cortical organization.FCD lesions were preferentially located in the prefrontal and fronto-limbic cortices typified by low neuron density, large soma and thick grey matter. Transcriptomic associations with FCD distribution uncovered a prenatal component related to neuroglial proliferation and differentiation, likely accounting for the dysplastic makeup, and a postnatal component related to synaptogenesis and circuit organization, possibly contributing to circuit-level hyperexcitability. FCD distribution showed a strong association with the anterior region of the antero-posterior axis derived from heritability analysis of interregional structural covariance of cortical thickness, but not with structural and functional hierarchical axes. Reliability of all results was confirmed through resampling techniques.Multimodal associations with cytoarchitecture, gene expression and axes of cortical organization indicate that prenatal neurogenesis and postnatal synaptogenesis may be key points of developmental vulnerability of the frontal lobe to FCD. Concordant with a causal role of atypical neuroglial proliferation and growth, our results indicate that FCD-vulnerable cortices display properties indicative of earlier termination of neurogenesis and initiation of cell growth. They also suggest a potential contribution of aberrant postnatal synaptogenesis and circuit development to FCD epileptogenicity.
Analysis of Female Participant Representation in Registered Oncology Clinical Trials in the United States from 2008 to 2020
Perera, Nirosha D. , Bellomo, Tiffany R. , Schmidt, Walker M. , Litt, Henry K. , Shyu, Margaret , Stavins, MaKenna A. , Wang, Max , Bell, Alexander , Saleki, Massoud , Wolf, Katherine I. , Ionescu, Ruxandra , Tao, Jacqueline J. , OʼKeefe, Ryan , Pun, Matthew , Takasugi, Jordan M., Turner, Brandon E. , Mahipal, Amit , Wang, Max M , Ji, Sunjong , O'Keefe, Ryan M , Pun, Matthew , Steinberg, Jecca R , Turner, Brandon E , Mahipal, Amit , Bell, Alexander , Ionescu, Ruxandra, Ji, Sunjong , Go, Ronald S.

Mayo Clinic

The Oncologist | February 27, 2023 | Volume: 28 | Issue: 6 | Pages: 510-519

10.1093/oncolo/oyad009 | PMID 36848266 Get It

Abstract Background Female underrepresentation in oncology clinical trials can result in outcome disparities. We evaluated female participant representation in US oncology trials by intervention type, cancer site, and funding. Materials and Methods Data were extracted from the publicly available Aggregate Analysis of ClinicalTrials.gov database. Initially, 270,172 studies were identified. Following the exclusion of trials using Medical Subject Heading terms, manual review, those with incomplete status, non-US location, sex-specific organ cancers, or lacking participant sex data, 1650 trials consisting of 240,776 participants remained. The primary outcome was participation to prevalence ratio (PPR): percent females among trial participants divided by percent females in the disease population per US Surveillance, Epidemiology, and End Results Program data. PPRs of 0.8-1.2 reflect proportional female representation. Results Females represented 46.9% of participants (95% CI, 45.4-48.4); mean PPR for all trials was 0.912. Females were underrepresented in surgical (PPR 0.74) and other invasive (PPR 0.69) oncology trials. Among cancer sites, females were underrepresented in bladder (odds ratio [OR] 0.48, 95% CI 0.26-0.91, P = .02), head/neck (OR 0.44, 95% CI 0.29-0.68, P < .01), stomach (OR 0.40, 95% CI 0.23-0.70, P < .01), and esophageal (OR 0.40 95% CI 0.22-0.74, P < .01) trials. Hematologic (OR 1.78, 95% CI 1.09-1.82, P < .01) and pancreatic (OR 2.18, 95% CI 1.46-3.26, P < .01) trials had higher odds of proportional female representation. Industry-funded trials had greater odds of proportional female representation (OR 1.41, 95% CI 1.09-1.82, P = .01) than US government and academic-funded trials. Conclusions Stakeholders should look to hematologic, pancreatic, and industry-funded cancer trials as exemplars of female participant representation and consider female representation when interpreting trial results.
Cerebral Small Vessel Disease–Related Dementia: More Questions Than Answers
Wang, Michael M. , Wang, Michael M , Elahi, Fanny M. , Meschia, James F.

Mayo Clinic

Stroke | February 27, 2023 | Volume: 54 | Issue: 3 | Pages: 648-660

10.1161/strokeaha.122.038265 | PMID 36848423 Get It

Cerebral small vessel disease (CSVD) has emerged as a common factor driving age-dependent diseases, including stroke and dementia. CSVD-related dementia will affect a growing fraction of the aging population, requiring improved recognition, understanding, and treatments. This review describes evolving criteria and imaging biomarkers for the diagnosis of CSVD-related dementia. We describe diagnostic challenges, particularly in the context of mixed pathologies and the absence of highly effective biomarkers for CSVD-related dementia. We review evidence regarding CSVD as a risk factor for developing neurodegenerative disease and potential mechanisms by which CSVD leads to progressive brain injury. Finally, we summarize recent studies on the effects of major classes of cardiovascular medicines relevant to CSVD-related cognitive impairment. Although many key questions remain, the increased attention to CSVD has resulted in a sharper vision for what will be needed to meet the upcoming challenges imposed by this disease.
Radiographic predictors of occult intracranial involvement in olfactory neuroblastoma patients
Geltzeiler, Mathew , Ji, Keven Seung Yong , JessMace, C., Almeida, John R. de , Champagne, Pierre‐Olivier , Chan, Erik, Ciporen, Jeremy , Chaskes, Mark B., Cornell, Sarah, Drozdowski, Veronica , Fernandez‐Miranda, Juan C. , Gardner, Paul A. , Hwang, Peter H. , Kalyvas, Aristotelis , Kong, Keonho A., McMillan, Ryan A. , Patel, Chirag , Patel, Zara M. , Celda, María Peris, Sanusi, Olabisi , Thorp, Brian D. , Zadeh, Gelareh , Zenonos, Georgios A. , Zwagerman, Nathan T. , Choby, Garret , Almeida, João Paulo , McMillan, Ryan A , Nayak, Jayakar V , Patel, Zara , Pinheiro-Neto, Carlos, Snyderman, Carl H , Wang, Eric W , Hwang, Peter H , Geltzeiler, Mathew , Choby, Garret , Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Gompel, Jamie J. Van

Mayo Clinic

International Forum of Allergy & Rhinology | February 26, 2023 | Volume: 13 | Issue: 10 | Pages: 1876-1888

10.1002/alr.23145 | PMID 36841933 Get It

AbstractBackgroundTraditional management of olfactory neuroblastoma (ONB) includes margin‐negative resection with removal of cribriform plate, dura, and olfactory bulb, regardless of intracranial disease. This approach may be overtreating certain patients. Our investigation examines risk factors associated with occult intracranial disease to optimize therapeutic outcomes.MethodsThis retrospective, multi‐institutional cohort study examined clinical covariates associated with occult intracranial involvement. Patient demographics, staging, Hyam's grade, and pathologic involvement of dura, olfactory bulb/tract, and brain were collected. Diagnostic imaging was reviewed. Positive and negative predictive value (NPV) were estimated along with effect size estimates. Cox hazard regression examined associations with overall survival (OS) and disease‐free survival (DFS).ResultsA total of 224 subjects with new diagnoses of ONB (2005–2021) were identified. Skull base bone involvement on computed tomography (CT) had the highest NPV for pathologic dura (88.0%), olfactory bulb (88%), and brain involvement (97.3%). Hyam's grade category was significantly associated with dural involvement (φC = 0.26; 95% confidence interval [CI]: 0.16, 0.42). Subjects without radiologic skull base involvement (n = 66) had pathologic positivity of 12.1%. Within this subgroup, Hyam's grade was clinically significant for dural positivity (φ = 0.34; 95% CI: −0.12, 0.71) with 28.6% involvement in high grade tumors. Neither clinical nor pathologic positivity of intracranial structures were associated with significantly different OS or DFS.ConclusionsBoth CT and magnetic resonance imaging (MRI) had reasonably good NPV for involvement of dura and olfactory bulb. Higher Hyam's grade was associated with dural involvement. Patients with low‐grade tumors not involving the skull base may be suitable for avoiding skull base resection; however, further investigation is warranted.
Educational Scoring System in Laparoscopic Cholecystectomy: Is It the Right Time to Standardize?
Reitano, Elisa , Famularo, Simone , Dallemagne, Bernard , Mishima, Kohei , Perretta, Silvana , Riva, Pietro , Addeo, Pietro , Asbun, Horacio J. , Conrad, Claudius , Demartines, Nicolas , Giménez, Mariano , Hogg, Melissa E. , Lin, Charles, Marescaux, Jacques , Memeo, Riccardo , Vix, Michel , Wang, Xiaoying , Mutter, Didier , Memeo, Riccardo , Marescaux, Jacques , Vix, Michel , Demartines, N , Fuks, David , Martinie, John B. , Soubrane, Olivier

Mayo Clinic

Medicina | February 24, 2023 | Volume: 59 | Issue: 3 | Pages: 446

10.3390/medicina59030446 | PMID 36984446 Get It

Background and Objectives: Laparoscopic cholecystectomy (LC) is one of the most performed surgeries worldwide. Procedure difficulty and patient outcomes depend on several factors which are not considered in the current literature, including the learning curve, generating confusing and subjective results. This study aims to create a scoring system to calculate the learning curve of LC based on hepatobiliopancreatic (HPB) experts’ opinions during an educational course. Materials and Methods: A questionnaire was submitted to the panel of experts attending the HPB course at Research Institute against Digestive Cancer-IRCAD (Strasbourg, France) from 27–29 October 2022. Experts scored the proposed variables according to their degree of importance in the learning curve using a Likert scale from 1 (not useful) to 5 (very useful). Variables were included in the composite scoring system only if more than 75% of experts ranked its relevance in the learning curve assessment ≥4. A positive or negative value was assigned to each variable based on its effect on the learning curve. Results: Fifteen experts from six different countries attended the IRCAD HPB course and filled out the questionnaire. Ten variables were finally included in the learning curve scoring system (i.e., patient body weight/BMI, patient previous open surgery, emergency setting, increased inflammatory levels, presence of anatomical bile duct variation(s), and appropriate critical view of safety (CVS) identification), which were all assigned positive values. Minor or major intraoperative injuries to the biliary tract, development of postoperative complications related to biliary injuries, and mortality were assigned negative values. Conclusions: This is the first scoring system on the learning curve of LC based on variables selected through the experts’ opinions. Although the score needs to be validated through future studies, it could be a useful tool to assess its efficacy within educational programs and surgical courses.
Comparison between mono‐tacrolimus and mono‐glucocorticoid in the treatment of myasthenia gravis
Fan, Zhirong , Lei, Lin, Su, Shengyao , Zhang, Shu , Xie, Nairong , Li, Ling , Di, Li , Wang, Min , Xu, Min , Shen, Xin‐Ming , Da, Yuwei , Shen, Xin-Ming , Da, Yuwei , Lü, Yan , Di, Li

Mayo Clinic

Annals of Clinical and Translational Neurology | February 21, 2023 | Volume: 10 | Issue: 4 | Pages: 589-598

10.1002/acn3.51746 | PMID 36808840 Get It

AbstractObjectiveUse of tacrolimus in mild to moderate myasthenia gravis (MG) is generally limited to glucocorticoid‐refractory cases; the advantage of mono‐tacrolimus over mono‐glucocorticoids is unknown.MethodsWe included mild to moderate MG patients treated with mono‐tacrolimus (mono‐TAC) or mono‐glucocorticoids (mono‐GC). The correlation between the immunotherapy options and the treatment efficacy and side effects were examined in 1:1 propensity‐score matching. The main outcome was time to minimal manifestations status or better (MMS or better). Secondary outcomes include time to relapse, the mean changes in Myasthenia Gravis‐specific Activities of Daily Living (MG‐ADL) scores and the rate of adverse events.ResultsBaseline characteristics showed no difference between matched groups (49 matched pairs). There were no differences in median time to MMS or better between the mono‐TAC group and mono‐GC group (5.1 vs. 2.8 months: unadjusted hazard ratio [HR], 0.73; 95% CI, 0.46–1.16; p = 0.180), as well as in median time to relapse (data unavailable for the mono‐TAC group since 44 of 49 [89.8%] participants remained in MMS or better; 39.7 months in mono‐GC group: unadjusted HR, 0.67; 95% CI, 0.23–1.97; p = 0.464). Changes in MG‐ADL scores between the two groups were similar (mean differences, 0.3; 95% CI, −0.4 to 1.0; p = 0.462). The rate of adverse events was lower in the mono‐TAC group compared to the mono‐GC group (24.5% vs. 55.1%, p = 0.002).InterpretationMono‐tacrolimus performs superior tolerability with non‐inferior efficacy compared to mono‐glucocorticoids in mild to moderate myasthenia gravis patients who refuse or have a contraindication to glucocorticoids.
Comorbid extra‐intestinal central sensitization conditions worsen irritable bowel syndrome in primary care patients
Wang, Xiao Jing , Ebbert, Jon O. , Loftus, Connor G., Rosedahl, Jordan K., Wang, Xiao Jing , Philpot, Lindsey M.

Mayo Clinic

Neurogastroenterology & Motility | February 20, 2023 | Volume: 35 | Issue: 4 | Pages: No page available

10.1111/nmo.14546 | PMID 36807964 Get It

AbstractBackgroundIrritable bowel syndrome (IBS) is characterized as a central sensitization syndrome (CSS), a group of conditions including fibromyalgia, chronic fatigue, and restless leg syndrome (RLS) among others with frequent comorbidities of anxiety, depression, and chemical sensitivity. The prevalence of comorbid conditions and their impact on IBS symptom severity and quality of life in rural community populations has not been described.MethodsWe administered a cross‐sectional survey to patients with a documented CSS diagnosis in rural primary care practices to evaluate the relationship between CSS diagnoses, quality of life, symptom severity, and interactions with healthcare providers utilizing validated questionnaires. Subgroup analysis was performed on the IBS cohort. Mayo Clinic IRB approved the study.Key ResultsSeven hundred seventy‐five individuals out of 5000 completed the survey (15.5% response rate) with 264 (34%) reporting IBS. Only 3% (n = 8) of IBS patients reported IBS alone without comorbid CSS condition. Most respondents reported overlapping migraine (196, 74%), depression (183, 69%), anxiety (171, 64%), and fibromyalgia (139, 52%). IBS patients with more than two comorbid CS condition showed significantly higher symptom severity with linear increase. Quality of life was lower in IBS with comorbid conditions, particularly in patients with IBS and RLS (mean EQ5‐D 0.36 vs. 0.8 in IBS only, p < 0.01). Quality of life declined as number of comorbid conditions increased.Conclusions & InferencesPatients with IBS often have multiple CS disorders which increases symptom severity and lowers quality of life. Understanding the impact of multiple CSS diagnoses and treating these as a global condition may improve patient experience.
Developing an Echocardiography-Based, Automatic Deep Learning Framework for the Differentiation of Increased Left Ventricular Wall Thickness Etiologies
Chao, Chieh‐Ju , Jeong, Jiwoong , Farina, Juan M. , Seri, Amith Reddy , Barry, Timothy , Newman, Hana , Campany, Megan , Abdou, Merna , O’Shea, Michael , Smith, Sean D. , Abraham, Bishoy, Hosseini, Seyedeh Maryam , Wang, Yuxiang , Lester, Steven J., Alsidawi, Said , Wilansky, Susan , Steidley, Eric, Rosenthal, Julie , Appleton, Christopher P., Shen, Win‐Kuang , Grogan, Martha , Kane, Garvan C. , Oh, Jae K. , Patel, Bhavik N. , Arsanjani, Reza , Banerjee, Imon , O’Shea, Michael , Chao, Chieh-Ju , Jeong, Jiwoong Jason, Farina, Juan M , Seri, Amith R, Barry, Timothy , O'Shea, Michael, Smith, Sean , Hosseini, Seyedeh Maryam , Lester, Steven, Alsidawi, Said , Arsanjani, Reza , Banerjee, Imon , Li, James , O’Shea, Michael, Abraham, Bishoy

Mayo Clinic

Journal of Imaging | February 20, 2023 | Volume: 9 | Issue: 2 | Pages: 48

10.3390/jimaging9020048 | PMID 36826967 Get It

Aims:Increased left ventricular (LV) wall thickness is frequently encountered in transthoracic echocardiography (TTE). While accurate and early diagnosis is clinically important, given the differences in available therapeutic options and prognosis, an extensive workup is often required to establish the diagnosis. We propose the first echo-based, automated deep learning model with a fusion architecture to facilitate the evaluation and diagnosis of increased left ventricular (LV) wall thickness. Methods and Results: Patients with an established diagnosis of increased LV wall thickness (hypertrophic cardiomyopathy (HCM), cardiac amyloidosis (CA), and hypertensive heart disease (HTN)/others) between 1/2015 and 11/2019 at Mayo Clinic Arizona were identified. The cohort was divided into 80%/10%/10% for training, validation, and testing sets, respectively. Six baseline TTE views were used to optimize a pre-trained InceptionResnetV2 model. Each model output was used to train a meta-learner under a fusion architecture. Model performance was assessed by multiclass area under the receiver operating characteristic curve (AUROC). A total of 586 patients were used for the final analysis (194 HCM, 201 CA, and 191 HTN/others). The mean age was 55.0 years, and 57.8% were male. Among the individual view-dependent models, the apical 4-chamber model had the best performance (AUROC: HCM: 0.94, CA: 0.73, and HTN/other: 0.87). The final fusion model outperformed all the view-dependent models (AUROC: HCM: 0.93, CA: 0.90, and HTN/other: 0.92). Conclusion: The echo-based InceptionResnetV2 fusion model can accurately classify the main etiologies of increased LV wall thickness and can facilitate the process of diagnosis and workup.